The ability of CD40 to promote DC maturation and presentation of tumour antigen indicates that CD40 based immunotherapies may be effective in combination with vaccination or radiotherapy, capable of inducing immunogenic tumour cell death, which is currently under investigation in a clinical trial (NCT03165994). Here, CD40 is linked to neoplasm.